SGAM
TGTX icon

Smith Group Asset Management’s TG Therapeutics TGTX Stock Holding History

Smith Group Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-120
Closed -$2K – 353
2021
Q4 		$2K Hold
120
– – ﹤0.01% 361
2021
Q3 		$4K Hold
120
– – ﹤0.01% 356
2021
Q2 		$5K Hold
120
– – ﹤0.01% 345
2021
Q1 		$6K Sell
120
-3,390
-97% -$163K ﹤0.01% 305
2020
Q4 		$183K Sell
3,510
-10
-0.3% -$338 0.01% 184
2020
Q3 		$94K Buy
+3,520
New +$81K ﹤0.01% 201
2014
Q3 		– Sell
-81,989
Closed -$770K – 430
2014
Q2 		$770K Sell
81,989
-112,712
-58% -$721K 0.03% 189
2014
Q1 		$1.34M Sell
194,701
-1,983
-1% -$11.7K 0.05% 172
2013
Q4 		$767K Buy
+196,684
New +$794K 0.03% 182

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Smith Group Asset Management's TGTX Position: Q1 2022 in Review

Smith Group Asset Management sold out of TG Therapeutics (TGTX) in Q1 2022, closing a stake of 120 shares — an estimated $2K sold.

Smith Group Asset Management first reported a position in TGTX in Q4 2013 and held it in 9 quarters. The position peaked at $1.34M in Q1 2014. 181 funds tracked by Wall St. Rank hold TGTX as of Q1 2022.

  • Smith Group Asset Management reported no remaining TG Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Smith Group Asset Management sold 120 TG Therapeutics shares in Q1 2022, an estimated $2K.
  • Smith Group Asset Management first reported a position in TG Therapeutics in Q4 2013 and held it in 9 quarters.
  • Smith Group Asset Management's TG Therapeutics position peaked at $1.34M in Q1 2014.
  • 181 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2022.

Based on Smith Group Asset Management's 13F filing for Q1 2022, filed 5 May 2022.